Hansa Biopharma has announced that its treatment Idefirix is, as of August 1, reimbursable and available for use in the Netherlands.
Idefirix is the first and only treatment approved for use in the European Union for desensitization of highly sensitized patients prior to kidney transplantation, allowing them to be considered for a life-altering kidney transplantation from a deceased donor.
Rare immunological conditions
Hansa Biopharma’s commercial launch activities throughout Europe are underway as planned, states the company in a press release. Pricing for Idefirix has been published in the first markets and the first commercial sales were reported in Q1 2021. The first agreements around reimbursement and funding access with healthcare providers and payers have been completed, and more are expected in the early-launch countries over the course of 2021, states the company.
“We are excited to be able to partner with the healthcare community in the Netherlands to offer a new therapy option for highly sensitized patients waiting for a potentially life-saving kidney transplant. This reimbursement announcement shows how we are delivering on our commitment to improve the lives of patients with rare immunological conditions,” says Henk Doude van Troostwijk, Senior Vice President and Chief Commercial Officer, Hansa Biopharma.